XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
    Assets measured at fair values on a recurring basis
    We measure and report our cash equivalents, restricted cash, marketable equity securities and available-for-sale debt securities at fair value on a recurring basis. The following tables summarize the fair value of these financial assets by significant investment category and their levels within the fair value hierarchy (in thousands):
 As of June 30, 2022As of December 31, 2021
Level ILevel IILevel IIITotal Level ILevel IILevel IIITotal
Financial Assets:
Cash Equivalents:
Money market funds $274,754 $— $— $274,754 $221,382 $— $— $221,382 
Commercial paper— 3,642 — 3,642 — — — — 
274,754 3,642 — 278,396 221,382 — — 221,382 
Marketable Securities:
Commercial paper— 18,462 — 18,462 — 141,274 — 141,274 
Certificate of deposits(1)
— 13,030 — 13,030 — 44,931 — 44,931 
U.S. government notes1,082,084 — — 1,082,084 1,057,810 — — 1,057,810 
Corporate bonds— 1,066,585 — 1,066,585 — 1,252,226 — 1,252,226 
Agency securities— 211,768 — 211,768 — 291,261 — 291,261 
Marketable equity securities(2)
16,727 — — 16,727 — — — — 
1,098,811 1,309,845 — 2,408,656 1,057,810 1,729,692 — 2,787,502 
Other Assets:
Money market funds - restricted4,258 — — 4,258 4,237 — — 4,237 
Total Financial Assets$1,377,823 $1,313,487 $— $2,691,310 $1,283,429 $1,729,692 $— $3,013,121 
______________________________________
(1) As of June 30, 2022 and December 31, 2021, all of our certificates of deposits were domestic deposits.
(2) The $16.7 million represents the fair value of marketable equity securities as of June 30, 2022. This amount includes $8.3 million that was reclassified from Investments on our condensed consolidated balance sheet following the commencement of public market trading of the issuer in January 2022. This publicly-traded equity investment generated an unrealized gain of $8.4 million for the six months ended June 30, 2022, and an unrealized loss of $5.1 million for the three months ended June 30, 2022. The unrealized gains and losses are included in Other income (expense), net on the Condensed Consolidated Statements of Operations. Refer to Note 3. Financial Statements Details.
    During the three and six months ended on June 30, 2022, the Company did not make any transfers between the levels of the fair value hierarchy.
    Marketable debt securities
    The following table summarizes the amortized cost, unrealized gains and losses, and fair value of our debt securities measured at fair value on a recurring basis (in thousands):
 As of June 30, 2022As of December 31, 2021
Amortized CostUnrealized GainsUnrealized LossesFair ValueAmortized CostUnrealized GainsUnrealized LossesFair Value
Commercial paper$18,462 $— $— $18,462 $141,274 $— $— $141,274 
U.S. government1,098,360 — (16,276)1,082,084 1,060,716 (2,909)1,057,810 
Corporate bonds1,083,803 (17,224)1,066,585 1,255,149 105 (3,028)1,252,226 
Agency securities214,687 (2,920)211,768 291,558 36 (333)291,261 
Total $2,415,312 $$(36,420)$2,378,899 $2,748,697 $144 $(6,270)$2,742,571 
    For debt securities in unrealized loss positions, it is not likely that we will be required to sell such securities before recovery of their amortized cost basis nor do we have the intent to sell such securities before maturity; we invest in debt securities that have maximum maturities of two years and are generally deemed to be low risk based on their credit ratings from the major rating agencies. The longer the duration of these marketable securities, the more susceptible they are to changes in market interest rates and bond yields. Given the short-term and conservative nature of our portfolio, the unrealized losses are not related to credit risk; therefore, we did not recognize any credit losses or non-credit-related impairments related to our available-for-sale marketable debt securities for the three and six months ended June 30, 2022. All unrealized losses were recognized in other comprehensive income (loss). Realized losses were immaterial for the three and six months ended June 30, 2022.
    The following table is an analysis of our marketable debt securities in unrealized loss positions (in thousands):
As of June 30, 2022
Unrealized Losses within 12 months Unrealized Losses 12 months or greaterTotal
Fair ValueUnrealized LossesFair ValueUnrealized LossesFair ValueUnrealized Losses
U.S. government notes$1,082,084 $(16,276)$— $— $1,082,084 $(16,276)
Corporate bonds995,771 (16,075)65,373 (1,149)1,061,144 (17,224)
Agency securities206,768 (2,920)— — 206,768 (2,920)
Total $2,284,623 $(35,271)$65,373 $(1,149)$2,349,996 $(36,420)
      As of June 30, 2022, we had no marketable debt securities with contractual maturities that exceed 24 months. The fair values of marketable debt securities, by remaining contractual maturities, are as follows (in thousands):
As of June 30, 2022
Fair Value
Due in 1 year or less$1,700,701 
Due in 1 to 2 years678,198 
Total debt securities $2,378,899 
    The weighted-average remaining duration of our marketable debt securities is approximately 0.8 years as of June 30, 2022. As we view these marketable debt securities as available to support current operations, we classify marketable debt securities with maturities beyond 12 months as current assets under the caption "Marketable securities" on the condensed consolidated balance sheets.
Assets measured at fair value on a non-recurring basis
    Non-Marketable Equity Securities
    We have non-marketable equity securities in privately-held companies that do not have readily-determinable fair values. These equity securities are included in Investments on the condensed consolidated balance sheets. Their initial cost is adjusted to fair value on a non-recurring basis based on observable price changes from orderly transactions of identical or similar securities of the same issuer, or for impairment. These investments are classified within Level III of the fair value hierarchy as we estimate the value based on valuation methods using the observable transaction price at the transaction date and other significant unobservable inputs, such as volatility, rights, and obligations related to these securities. In addition, the valuation requires management judgment due to the absence of market price and lack of liquidity.
    We did not record any realized gains or losses for our non-marketable equity securities measured at fair value on a non-recurring basis during the three and six months ended June 30, 2022 and June 30, 2021. We recorded an unrealized gain of $15.0 million on non-marketable equity securities based on observable price changes from orderly transactions of identical or similar securities of the same issuer in the six months ended June 30, 2022, but did not record any unrealized losses or additional unrealized gains in the three months ended June 30, 2022 and the three and six months ended June 30, 2021. We evaluate our non-marketable equity securities for impairment at each reporting period via a qualitative assessment with various potential impairment indicators, including, but not limited to, an assessment of a significant adverse change in the economic environment, significant adverse changes in the general market condition of the geographies and industries in which our investees operate, and other publicly-available information that affected the value of the its non-marketable equity securities.
    The following table summarizes the activity related to our non-marketable equity securities as of June 30, 2022 and December 31, 2021 (in thousands):
June 30, 2022December 31, 2021
Cost of investments (1)$23,263 $14,933 
Cumulative impairment— — 
Cumulative upward adjustment (1)15,000 5,314 
Carrying amount of investments$38,263 $20,247 
(1) During the six months ended June 30, 2022, $3.0 million previously included in the Cost of investments and $5.3 million previously included in the Cumulative upward adjustment, or $8.3 million in aggregate, were reclassified from Investments to Marketable securities on our condensed consolidated balance sheet following the commencement of public market trading of the issuer. There was no such activity in the three months ended June 30, 2022.